Denali Therapeutics (NASDAQ:DNLI) Price Target Raised to $26.00

Denali Therapeutics (NASDAQ:DNLI) had its price target upped by JPMorgan Chase & Co. from $24.00 to $26.00 in a research report report published on Tuesday,Benzinga reports. They currently have an overweight rating on the stock.

DNLI has been the topic of a number of other research reports. TD Cowen raised shares of Denali Therapeutics to a “strong-buy” rating in a report on Monday, July 28th. Morgan Stanley reduced their target price on shares of Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating on the stock in a research report on Monday, August 18th. Cantor Fitzgerald reissued an “overweight” rating on shares of Denali Therapeutics in a report on Monday, September 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $32.64.

Denali Therapeutics Trading Down 3.2%

DNLI stock opened at $14.41 on Tuesday. The business has a fifty day moving average price of $15.08 and a 200 day moving average price of $14.67. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.27 and a quick ratio of 10.27. Denali Therapeutics has a fifty-two week low of $10.57 and a fifty-two week high of $33.33. The stock has a market capitalization of $2.11 billion, a price-to-earnings ratio of -5.15 and a beta of 1.39.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.74) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.02. During the same period last year, the business posted ($0.63) earnings per share. Denali Therapeutics’s revenue was up .0% on a year-over-year basis. Analysts expect that Denali Therapeutics will post -2.71 EPS for the current fiscal year.

Insider Buying and Selling at Denali Therapeutics

In related news, insider Carole Ho sold 2,937 shares of Denali Therapeutics stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total transaction of $39,884.46. Following the completion of the sale, the insider directly owned 217,391 shares of the company’s stock, valued at $2,952,169.78. The trade was a 1.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Alexander O. Schuth sold 2,937 shares of the stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total value of $39,884.46. Following the completion of the transaction, the insider directly owned 242,346 shares in the company, valued at $3,291,058.68. The trade was a 1.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 6,680 shares of company stock worth $91,569 over the last 90 days. 12.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Headlands Technologies LLC acquired a new stake in shares of Denali Therapeutics in the 2nd quarter valued at about $26,000. State of Wyoming bought a new position in shares of Denali Therapeutics during the second quarter worth about $29,000. Caitong International Asset Management Co. Ltd raised its position in Denali Therapeutics by 277.0% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company’s stock valued at $29,000 after buying an additional 1,551 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Denali Therapeutics in the 1st quarter valued at approximately $41,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Denali Therapeutics by 15.5% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company’s stock valued at $79,000 after acquiring an additional 753 shares in the last quarter. Institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.